Increased left ventricular mass in chronic kidney disease and end-stage renal disease: What are the implications?

Dialysis and Transplantation

Volumn 39, Issue 1, 2010, Pages 16-19

  Glassock, Richard J ^a   Pecoits Filho, Roberto ^b   Barbareto, Silvio ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARNITINE; CARVEDILOL; CINACALCET; ERYTHROPOIETIN; GADOLINIUM; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PARATHYROID HORMONE; PHOSPHATE; RENIN INHIBITOR; SILDENAFIL; TROPONIN T; VITAMIN D;

ANEMIA; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CALCIFICATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MORBIDITY; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PERITONEAL DIALYSIS; PHYSICAL EXAMINATION; PREVENTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK REDUCTION; SCIENTIFIC LITERATURE; SENSITIVITY AND SPECIFICITY; SODIUM BLOOD LEVEL; SODIUM RESTRICTION; SUDDEN DEATH; THORAX RADIOGRAPHY; TREATMENT INDICATION; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VITAMIN D DEFICIENCY;

EID: 76749122017     PISSN: 00902934     EISSN: 19326920     Source Type: Journal    
DOI: 10.1002/dat.20391     Document Type: Article

References (39)

1. Ritz E, Wanner C. The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol. 2008;3:920-929.
2. Glassock R, Pecoits-Filho R, Barbareto SH. Left ventricular mass in chronic kidney disease and end-stage renal disease. Clin J Am Soc Nephrol. In press.
3. Stewart GA, Foster J, Cowan M, et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int. 1999;56:2248-2253.
4. Mark PB, Patel RK, Jardine AG. Are we overestimating left ventricular abnormalities in end-stage renal disease? Nephrol Dial Transplant. 2007;22:1815-1819.
5. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
6. Malik J, Tuka V, Mokrejsova M, et al. Mechanisms of chronic heart failure development in end-stage renal disease patients on chronic hemodialysis. Physiol Res. 2008.
7. Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008;19:1643-1652.
8. Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2001;12:2768-2774
9. McMahon LP, Roger SD, Levin A. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol. 2004;15:1640-1647.
10. Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004;65:1492-1498.
11. Paoletti E, Bellino D, Cassottana P, et al. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis. 2005;46:320-327.
12. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298:1291-1299.
13. Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol. 2005;16:2778-2788.
14. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol 2009;4:755-762.
15. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180-2189.
16. Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int. 2009;75:771-773.
17. Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol. 2009;4:914-920.
18. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12:2759-2767.
19. Wanner C, Krane V. Lessons learnt from the 4D trial. Nephrol Ther. 2006;2:3-7.
20. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-1407.
21. Paoletti E, Amidone M, Cassottana P, et al. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis. 2008;52:324-330.
22. Suri RS, Garg AX, Chertow GM, et al. Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int. 2007;71:349-359.
23. Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia-beyond coronary heart disease. Semin Dial. 2008;21:308-318.
24. Diwan A, Wansapura J, Syed FM, et al. Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation. 2008;117:396-404.
25. de Paula FM, Peixoto AJ, Pinto LV, Patricio PJ, Santos SP. Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int. 2004;66:1232-1238.
26. Oberleithner H, Riethmuller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M. Plasma sodium stiffens vascular enothelium and reduces nitric oxide release. Proc Natl Acad Sci U S A. 2007;41:16281-16286.
27. Strozecki P, Adamowicz A, Nartowicz E, et al. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail. 2001;23:115-126.
28. Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A. 2007;104:16810-16815.
29. Fujii H, Kim JI, Abe T, et al. Relationship between parathyroid hormone and cardiac abnormalities in chronic dialysis patients. Intern Med. 2007;46:1507-1512.
30. Cridlig J, Selton-Suty C, Alla F, et al. Cardiac impact of the arteriovenous fistula after kidney transplantation: a case-controlled, match-paired study. Transplant Int. 2008;21:948-954.
31. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int. 2009;75:800-808.
32. Tian JP, Wang T, Wang H, et al. The prevalence of left ventricular hypertrophy in Chinese hemodialysis patients is higher than that in peritoneal dialysis patients. Renal Failure. 2008;30:391-400.
33. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438-1444.
34. Sakhuja R, Keebler M, Lai TS, et al. Meta-analysis of mortatlity in dialysis patients with an implantable cardioverter defibrillator. Am J Cardiol. 2009;103:735-741.
35. Koleganova N, Piecha G, Ritz E, et al. Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic. Lab Invest. 2009;89:520-530.
36. Koleganova N, Piecha G, Ritz E, Gross ML. Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant. 2009;24:778-787.
37. Paoletti E, Amidone M, Cassottana P, et al. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis. 2008;52:324-330.
38. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant. 2006;21:854-858.
39. Fuuji H, Nishijima F, Goto S, et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac daamge in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant. 2009;24:2089-2095